Literature DB >> 15259501

Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis.

Yoshihisa Urita1, Kazuo Hike, Naotaka Torii, Yoshinori Kikuchi, Eiko Kanda, Masahiko Sasajima, Kazumasa Miki.   

Abstract

The importance of atrophic gastritis with intestinal metaplasia is related to the fact that it increases the risk of gastric cancer development. The aim of this study is to evaluate the diagnostic potential of serum pepsinogens in predicting the topography of intestinal metaplasia. Both dye endoscopy and 13C-urea breath test were carried out in 878 subjects. Serum pepsinogen I, pepsinogen II, and IgG antibody to Helicobacter pylori were measured. The overall prevalence of intestinal metaplasia was higher in subjects with lower PG I/II ratios and lower PG I values. Based on ROC curves, a cutoff value for pepsinogen I/II ratio of less than 3.0 would have identified intestinal metaplasia with a sensitivity of 71.7% and a specificity of 66.7% in Helicobacter pylori-positive subjects. It is possible that serum pepsinogens could be used as a screening test for high-risk subjects with intestinal metaplasia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259501     DOI: 10.1023/b:ddas.0000030091.92379.91

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  40 in total

1.  Serum pepsinogens as a screening test of extensive chronic gastritis.

Authors:  K Miki; M Ichinose; A Shimizu; S C Huang; H Oka; C Furihata; T Matsushima; K Takahashi
Journal:  Gastroenterol Jpn       Date:  1987-04

2.  Precancerous gastric lesions and Helicobacter pylori.

Authors:  E Masci; E Viale; M Freschi; M Porcellati; A Tittobello
Journal:  Hepatogastroenterology       Date:  1996 Jul-Aug

Review 3.  The etiology of gastric cancer. Intragastric nitrosamide formation and other theories.

Authors:  S S Mirvish
Journal:  J Natl Cancer Inst       Date:  1983-09       Impact factor: 13.506

4.  Estimates of the worldwide incidence of 25 major cancers in 1990.

Authors:  D M Parkin; P Pisani; J Ferlay
Journal:  Int J Cancer       Date:  1999-03-15       Impact factor: 7.396

5.  Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies.

Authors:  M T Al-Assi; K Miki; J H Walsh; D P Graham; M Asaka; D Y Graham
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  A sensitive and specific serologic test for detection of Campylobacter pylori infection.

Authors:  D J Evans; D G Evans; D Y Graham; P D Klein
Journal:  Gastroenterology       Date:  1989-04       Impact factor: 22.682

Review 7.  Helicobacter pylori and gastric carcinogenesis.

Authors:  P Correa
Journal:  Am J Surg Pathol       Date:  1995       Impact factor: 6.394

8.  Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. The EUROGAST Study Group.

Authors: 
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

9.  Helicobacter pylori serology in patients with chronic gastritis.

Authors:  M Plebani; D Basso; M Cassaro; L Brigato; M Scrigner; A Toma; F Di Mario; M Rugge
Journal:  Am J Gastroenterol       Date:  1996-05       Impact factor: 10.864

10.  The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects.

Authors:  K Miki; M Ichinose; N Kawamura; M Matsushima; H B Ahmad; M Kimura; J Sano; T Tashiro; N Kakei; H Oka
Journal:  Jpn J Cancer Res       Date:  1989-02
View more
  11 in total

1.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

2.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

3.  Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study.

Authors:  Daisuke Chinda; Tadashi Shimoyama; Tatsuya Mikami; Tetsu Arai; Daisuke Chiba; Yoshio Sasaki; Kazuo Komai; Yoshihiko Sawada; Yoshiharu Saito; Hironobu Chiba; Shinsaku Fukuda
Journal:  J Gastroenterol       Date:  2018-01-20       Impact factor: 7.527

4.  Identification of Helicobacter pylori-related gastric cancer risk using serological gastritis markers and endoscopic findings: a large-scale retrospective cohort study.

Authors:  Naoko Nagasaki; Masanori Ito; Tomoyuki Boda; Takahiro Kotachi; Hidehiko Takigawa; Shiro Oka; Shinji Tanaka
Journal:  BMC Gastroenterol       Date:  2022-06-20       Impact factor: 2.847

5.  Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach.

Authors:  Katsunori Iijima; Yasuhiko Abe; Ryosuke Kikuchi; Tomoyuki Koike; Shuichi Ohara; Pentti Sipponen; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

6.  Atrophic gastritis, but not antibody to Helicobacter pylori, is associated with body mass index in a Japanese population.

Authors:  Takehiro Torisu; Takayuki Matsumoto; Yutaka Takata; Toshihiro Ansai; Inho Soh; Shuji Awano; Ikuo Nakamichi; Shuntaro Kagiyama; Kazuo Sonoki; Akihiro Yoshida; Tomoko Hamasaki; Mitsuo Iida; Tadamichi Takehara
Journal:  J Gastroenterol       Date:  2008-10-29       Impact factor: 7.527

Review 7.  Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod.

Authors:  David Y Graham; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2009-08-28       Impact factor: 7.527

8.  Multifaceted Assessment of Chronic Gastritis: A Study of Correlations between Serological, Endoscopic, and Histological Diagnostics.

Authors:  Toshitatsu Takao; Takeshi Ishikawa; Takashi Ando; Madoka Takao; Tsuguhiro Matsumoto; Yutaka Isozaki; Mika Okita; Yasuyuki Nagao; Hirokazu Oyamada; Keiichi Yokoyama; Atsushi Tatebe; Kazuhiko Uchiyama; Osamu Handa; Tomohisa Takagi; Nobuaki Yagi; Satoshi Kokura; Yuji Naito; Toshikazu Yoshikawa
Journal:  Gastroenterol Res Pract       Date:  2011-07-10       Impact factor: 2.260

Review 9.  Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method".

Authors:  Kazumasa Miki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2011       Impact factor: 3.493

Review 10.  Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers.

Authors:  Lars Agréus; Ernst J Kuipers; Limas Kupcinskas; Peter Malfertheiner; Francesco Di Mario; Marcis Leja; Varocha Mahachai; Niv Yaron; Martijn van Oijen; Guillermo Perez Perez; Massimo Rugge; Jukka Ronkainen; Mikko Salaspuro; Pentti Sipponen; Kentaro Sugano; Joseph Sung
Journal:  Scand J Gastroenterol       Date:  2012-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.